TITLE

FAVORABLE PHASE 2A CLINICAL TRIAL SAFETY DATA FOR GLYPROMATE

PUB. DATE
October 2006
SOURCE
Worldwide Biotech;Oct2006, Vol. 18 Issue 10, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the pharmacokinetics analysis of the Phase 2 clinical trial of lead compound Glypromate announced by Neuren Pharmaceuticals in 2006. The study aims to analyze the role of Glypromate in the reduction of cognitive decline following cardiac surgery. It reveals the percentage of patients with cognitive impairment at discharge from cardiac surgery. Moreover, views of Doug Wilson, chief medical officer of Neuren, on the clinical trial are presented.
ACCESSION #
22401421

 

Related Articles

  • Industry SnapShots.  // Acquisdata Industry SnapShot: Australia Biotechnology;12/2/2015, Issue 3855, preceding p1 

    The article focuses on the biotechnology and pharmaceuticals industry in Australia and tackles topics including synapse discovery which could lead to new treatments for Alzheimer's disease, public health bill by investing in new medicines, and grants receive by Neuren Pharmaceuticals Ltd.

  • different strokes. Doggrell, Sheila // Investigate;Oct2005, Vol. 5 Issue 57, p52 

    Deals with the efforts of New Zealand company Neuren to develop drugs to help people who suffer brain damage from strokes, road accidents and heart attacks. Claims of Neuren about its glypromate product; Reason for the devastating effect of stroke; Distinction between ischemic and hemorrhagic...

  • Neuren Acquires Hamilton, Gets Phase II CNS Drug. Morrison, Trista // BioWorld Today;8/1/2007, Vol. 18 Issue 148, p1 

    The article reports that Neuren Pharmaceuticals Ltd. has acquired Hamilton Pharmaceuticals Inc. The deal has yet to be approved by Neuren shareholders. According to Lawrence Glass, Neuren's executive vice president of biology, the company is excited with Hamilton's drug for central nervous...

  • Stroke drug earns phase-3 trial. Walters, Kath // BRW;2/8/2007, Vol. 29 Issue 5, p12 

    The article reports that biotechnology company Neuren Pharmaceuticals Ltd. has received approval from the U.S. Food and Drug Administration (FDA) to begin a phase three drug trial of Glypromate, which is designed to prevent cognitive impairment in heart-surgery patients. If the trial is...

  • Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design. Lima, L�dia Moreira; Barreiro, Eliezer J. // Current Medicinal Chemistry;2005, Vol. 12 Issue 1, p23 

    This review aim to demonstrate the role of bioisosterism in rational drug design as well as in the molecular modification and optimization process aiming to improve pharmacodynamic and pharmacokinetic properties of lead compounds.

  • Translational Biomarkers. Caberlotto, Laura // Contract Pharma;Sep2011, Vol. 13 Issue 7, p106 

    The article discusses aspects of translational biomarkers in the U.S. It highlights the importance of predictive biomarkers in preclinical drug discovery and development as well as in transnational activities. It cites the predictive biomarkers that facilitate the selection of lead compounds for...

  • In Vivo Activity and Pharmacokinetics of Nemorosone on Pancreatic Cancer Xenografts. Wolf, Robert J.; Hilger, Ralf A.; Hoheisel, Jörg D.; Werner, Jens; Holtrup, Frank // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Pancreatic cancer is one of the leading cancer-related causes of death in the western world with an urgent need for new treatment strategies. Recently, hyperforin and nemorosone have been described as promising anti-cancer lead compounds. While hyperforin has been thoroughly investigated in...

  • Glycopeptide pharmacokinetics in current paediatric cardiac surgery practice Shime, Nobuaki; Kato, Yuko; Kosaka, Tadashi; Kokufu, Takatoshi; Yamagishi, Masaaki; Fujita, Naohisa // European Journal of Cardio-Thoracic Surgery;Oct2007, Vol. 32 Issue 4, p577 

    Abstract: Objective: To examine the evolution of serum concentrations of prophylactic glycopeptides administered during state-of-the-art cardiopulmonary bypass (CPB) and vigorous haemodiafiltration in paediatric patients undergoing cardiac surgery. Methods: We enrolled infants and children <3...

  • Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery. Garcia, Maria Pilar Ortega; Marti-Bonmati, Ezequiel; Serrano, Javier Guevara; Gomez, Isabel Gil // American Journal of Health-System Pharmacy;2/15/2003, Vol. 60 Issue 4, p260 

    Studies the alteration of vancomycin pharmacokinetics during cardiopulmonary bypass (CPB) in patients undergoing cardiac surgery. Patient characteristics; Vancomycin pharmacokinetic values; Serum vancomycin concentrations of patients; Biochemical and pharmacokinetic values before, during and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics